Peptides Explained

True-Sciences.com use code Pep20 for 20% off your first order

Dr. Hany Demian joins John Garrett for a conversation about chronic pain, injury recovery, regenerative medicine, and where peptides may fit in patient care.

Drawing on his clinical experience, Dr. Demian discusses how he approaches patients with different needs, why he avoids a "kitchen sink" approach, and why sleep, nutrition, exercise, and careful assessment still matter. They also talk about clinical judgment, patient safety, and situations where peptides may not be appropriate.

The conversation includes clinical anecdotes and personal perspectives. These do not establish that a peptide is safe or effective. Evidence for compounds such as BPC-157 and TB-500 remains limited. This episode is for educational purposes and is not individualized medical advice.

In this revisit, John Garrett looks at BPC-157's proposed biology, the three small published human reports, new clinical-trial registry entries, the FDA advisory committee's recommendation, and HHS's October 30 interim enforcement-discretion policy. The published human record remains small and very low certainty.

For BPC-157, the HHS policy identifies the acetate form and specified dosage forms under limited Section 503A circumstances. It is conditional and interim; it does not make BPC-157 FDA-approved, add it to the 503A Bulks List, or establish that it works. We also explain why the anti-doping rules are a separate question.

This episode is for informational purposes only and is not medical advice. Research and policy details were checked October 30, 2026; verify current status before publication.

What if the future of regenerative medicine isn't just about stem cells—but the biological messages those cells send?

In this episode of Peptides Explained, John Garrett sits down with Sanjiv Lal, founder of Cell Factor and co-founder of Regen Therapy, to explore the emerging science of secretomes, cellular communication, and regenerative medicine.

Sanjiv shares his personal journey from pharmaceutical sciences and molecular diagnostics to becoming a patient facing significant health challenges. That experience sparked his interest in cell-free regenerative technologies and the biological signaling systems involved in tissue repair, inflammation, and aging.

Together, John and Sanjiv explore:

• Secretome science: What secretomes are and how they differ from stem cells and exosomes.

• Cellular communication: How peptides, growth factors, cytokines, and extracellular vesicles influence biological signaling.

• Cell Factor: Sanjiv's explanation of the technology, manufacturing process, and potential applications.

• Mitochondrial health: The relationship between cellular energy, inflammation, and biological function.

• Healthspan vs. lifespan: Why extending healthy, functional years matters as much as extending life.

• Peptides and longevity: Sanjiv's personal experience with Cell Factor, SS-31, MOTS-c, and other interventions.

• The future of healthcare: The potential role of preventive medicine, personalized diagnostics, and emerging regenerative technologies.

Sanjiv also discusses his own health improvements and his vision for expanding access to regenerative medicine through Regen Therapy and related ventures.

The bigger question: Can scientists harness cellular signaling to improve human health, and what clinical evidence will be needed to demonstrate that these approaches are safe and effective?

This is a conversation about scientific possibility, innovation, and taking a more active role in long-term health.

Learn more: Cell Factor: https://cell.health/

RegenTherapy https://regentherapy.com

Important disclaimer: This episode is for educational purposes only and does not constitute medical advice. Cell Factor and the experimental approaches discussed should not be considered proven treatments for kidney disease, diabetes, aging, or other medical conditions. Personal experiences are not controlled clinical evidence. Consult a qualified healthcare professional before making treatment decisions.

True-Sciences.com Use Code Pep20 for 20% off.

A careful look at CJC-1295: the growth-hormone pathway, the distinction between DAC and no-DAC naming, what small human studies measured, the terminated Phase 2 trial, current FDA compounding information, the unproven CJC-1295/ipamorelin combination claims, and WADA's 2026 rules. The evidence supports a hormone effect for the long-acting DAC-modified compound; it does not establish the benefits often marketed for consumer products. Educational content only; not medical advice. Snapshot checked October 19, 2026.

seed oils, cooking fats, inflammation, omega-6 and omega-3, food labels, nutrition, and healthy cooking.

Eli Lilly is taking legal action against businesses selling products labeled retatrutide. What do the lawsuits actually establish—and what don't they? John Garrett separates pending legal allegations from court findings, reviews the human trial evidence for the investigational triple agonist, and explains why molecular identity, purity, and pharmaceutical equivalence are not interchangeable. We also examine FDA restrictions, consumer safety, and the implications for clinics, vendors, and independent educators. Educational only; not medical or legal advice. Retatrutide is not FDA-approved. Sources: NEJM DOI 10.1056/NEJMoa2301972; FDA unapproved GLP-1 drug concerns; ClinicalTrials.gov NCT05929066 and NCT05882045.

Can peptide biology protect the brain from vascular damage? John follows a question that started with Vesugen into the biology of vascular cognitive impairment—endothelial dysfunction, hypoperfusion, blood-brain-barrier injury, mitochondrial stress, inflammation and neuronal damage. The episode maps Cerebrolysin, SS-31/elamipretide, ARA-290/cibinetide, Semax, Vesugen and GLP-1 receptor agonists onto different points in that cascade, then asks the question that matters: what does the human evidence actually support? Cerebrolysin provides the biggest surprise, with randomized vascular-dementia trials—but still low-certainty evidence. Educational only; not medical advice.

Everyone keeps calling belly fat "visceral fat." That is not how anatomy works. In this crossover episode, John breaks down the difference between visceral and subcutaneous fat, why visceral adipose tissue matters metabolically, how it is actually measured, what waist circumference can and cannot tell you, and what the evidence says about GLP-1 therapies and tesamorelin.

Vesugen is only three amino acids long: lysine, glutamate, and aspartate — KED. Yet it is promoted as a vascular bioregulator that may support endothelial health and even "rejuvenate" aging blood vessels.

In this episode, John Garrett looks at what the endothelial research actually measured, the proposed gene-regulation mechanism, a small human blood-flow report, and the large gap between an interesting cell signal and a proven cardiovascular therapy.

No hype. No dismissal. Just the biology, the evidence, and what remains unknown.

INSTAGRAM CAPTION

Three amino acids.

K. E. D.

And somehow that became a claim about "rejuvenating" aging blood vessels.

Vesugen is one of the more interesting Khavinson bioregulator peptides because there is actual published endothelial-cell research behind the concept.

But there is a big difference between:

changing a cell marker

improving endothelial function

and preventing cardiovascular disease.

In the new episode of Peptides Explained, I break down the mechanism, the human signal, the evidence gaps, and the question that matters most:

Can Vesugen actually make aging blood vessels younger — or is the marketing way ahead of the science?

Educational only. Not medical advice.

#PeptidesExplained #Vesugen #KEDPeptide #Peptides #Longevity #VascularHealth #EndothelialHealth #CardiovascularHealth #HealthyAging #Biohacking #PeptideScience #MedicalScience

FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.